•  
  •  
  •  
  •  

2025-12-23 19:16:54

  • Home
  • Commodities
  • Industry News
  • IPO
  • Mutual Funds
  • Others
  • Research
  • Watch List
Latest News
  • Biocon Ltd signs out-licensing agreement with Ajanta to market Semaglutide in 26 countries
  • Axis Bank Launches Digital Merchant Cash Advance Loans for MSMEs
  • Shakti Pumps India Ltd receives LoA worth Rs. 356.77 crores from MSEDCL
  • Surana Telecom and Power Ltd awarded 8 LOAs for 51.3 MW solar projects
  • Vikran Engineering Ltd accepts order received from Onix Renewables Ltd

Keywords Selected:  INE935A01035

Stock Report

  • Glenmark Pharmaceuticals Inc., USA launches Epinephrine Injection USP, 30 mg/30 mL (1 mg/mL) Multiple-Dose Vial
  • Glenmark Secures Exclusive Multi-Regional Rights to Aumolertinib, an MHRA and NMPA approved Third-Generation EGFR-TKI, from Hansoh Pharma
  • Glenmark Secures Exclusive Multi-Regional Rights to Aumolertinib, an MHRA and NMPA approved Third-Generation EGFR-TKI, from Hansoh Pharma
  • Glenmark Pharmaceuticals Inc., USA to launch Leucovorin Calcium for Injection USP, 350 mg/vial Single-Dose Vial
  • Glenmark Pharmaceuticals Ltd update on USFDA PAI at Chhatrapati Sambhajinagar Facility
  • Glenmark Pharmaceuticals Receives Establishment Inspection Report (EIR) from U.S. FDA for its Monroe facility
  • Glenmark Pharmaceuticals announces Launch of Nebzmart® GFB Smartules® and Glenmark Airz® FB Smartules®, World's First Nebulized Triple Therapy for COPD
  • Cosmo and Glenmark announce Market Authorization of Winlevi® (clascoterone) 10 mg/g cream for Treatment of Acne in 15 countries in Europe
  • Glenmark Pharmaceuticals Announces Q2FY26 Results
  • Glenmark Secures China Approval For RYALTRIS®, Reinforcing Respiratory Innovation Leadership
  • Glenmark Pharmaceuticals Inc., USA to launch 8.4% Sodium Bicarbonate Injection USP, 50 mEq/50 mL (1 mEq/mL) Single-Dose Vial
  • Glenmark Pharmaceuticals Inc., USA to launch Ropivacaine Hydrochloride Injection USP
  • Glenmark Strengthens Oncology Portfolio with Hengrui's HER2 Targeting ADC For Multiple Regions
  • Glenmark Pharma arm receives upfront payment of $700 Mn from AbbVie
  • Glenmark Pharmaceuticals Inc., USA to launch Eribulin Mesylate Injection, 1mg/2Ml (0.5 mg/mL) Single-Dose Vials
  • Glenmark Pharmaceuticals Inc., USA to launch Micafungin for Injection USP, 50 mg/vial and 100 mg/vial
  • Ichnos Glenmark Innovation announces Global Commercialization Strategy for ISB 2001 Following Licensing Deal with AbbVie
  • Ichnos Glenmark Innovation and AbbVie announce Exclusive Global Licensing Agreement for ISB 2001, a First-in-Class CD38×BCMA×CD3 Trispecific Antibody
  • Glenmark Pharmaceuticals Launches TEVIMBRA® in India
  • U.S. FDA inspection at Glenmark Pharma's Facility at Monroe, North Carolina, USA
  • Glenmark Pharmaceuticals to Launch DCGI-approved BRUKINSA® in India to Advance Treatment of Hematological Malignancies
  • Ichnos Glenmark Innovation receives U.S. FDA Fast Track Designation for ISB 2001 for Relapsed/Refractory Multiple Myeloma
  • Glenmark Pharmaceuticals Inc., USA to launch Dextroamphetamine Saccharate, Amphetamine Aspartate, Dextroamphetamine Sulfate and Amphetamine Sulfate Tablets
  • Glenmark Pharmaceuticals Inc., USA launches Vancomycin Hydrochloride for Injection USP, 750 mg/vial, 1.25 g/vial and 1.5 g/vial (Single-Dose Vial)

Latest Post

  • Biocon Ltd signs out-licensing agreement with Ajanta to market Semaglutide in 26 countries
  • Axis Bank Launches Digital Merchant Cash Advance Loans for MSMEs
  • Shakti Pumps India Ltd receives LoA worth Rs. 356.77 crores from MSEDCL
  • Surana Telecom and Power Ltd awarded 8 LOAs for 51.3 MW solar projects
  • Vikran Engineering Ltd accepts order received from Onix Renewables Ltd


Announcement

To Advertise in our website please e-mail us at advertisement@equitybulls.com
Companies can send their Press Releases to pressrelease@equitybulls.com

Links

  • Home
  • Contact
  • Our Team

Contact

The website is developed and maintained by Chennai Scripts
C-4, Podhigai Flats, Pillayar Koil Street, Nesapakkam
Chennai
Tamil Nadu
India
600078
E-mail: chennaiscripts@gmail.com
Mobile Phone Number: +91-88776-69935
www.chennaiscripts.com

Website Created & Maintained by : Chennai Scripts
Nesapakkam, Chennai - 600 078,
Tamil Nadu, India

Disclaimer Copyright © - 2024